Neuraxpharm and Panaxia have signed two addendums to an existing agreement that will allow the partners to market medical cannabis in the Czech and Swiss markets.
Israeli firm Panaxia – a global specialist in pharmaceutical-quality cannabis products – will manage the manufacturing of pharmaceutical-grade medical cannabis premium oils and extracts for inhalation
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Generics Bulletin for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?